azimilide has been researched along with amiodarone in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 20 (83.33) | 29.6817 |
| 2010's | 4 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Du, L; Li, M; Tang, Y; Xia, L; Yang, Q; You, Q | 1 |
| Sen, S; Sinha, N | 1 |
| Sager, PT | 1 |
| Camm, AJ | 1 |
| Bianconi, L; Castro, A; Santini, M | 1 |
| Grönefeld, GC; Hohnloser, SH | 1 |
| Wolbrette, DL | 1 |
| Khan, MH | 1 |
| Li, WZ | 1 |
| Singh, S | 1 |
| Bleich, M; Brendel, J; Busch, AE; Knobloch, K; Rosenstein, B; Wirth, KJ | 1 |
| Brendorp, B; Elming, H; Køber, L; Pedersen, OD; Pehrson, S; Torp-Petersen, C | 1 |
| Gerstenfeld, EP; Marchlinski, FE; Nayak, H; Patel, VV; Rajawat, YS | 1 |
| Cvetanovic, I; Ke, X; Lin, C; Ranade, V; Somberg, J | 1 |
| Reiffel, JA | 1 |
| Sharma, S | 1 |
| Conway, E; Kowey, PR; Musco, S | 1 |
| Tang, YQ; Wang, XJ; Yang, Q; You, QD | 1 |
| Furutani, K; Inanobe, A; Iwata, M; Kurachi, Y; Ohno, Y; Yamakawa, Y | 1 |
| Anderson, JL; Bunch, TJ | 1 |
13 review(s) available for azimilide and amiodarone
| Article | Year |
|---|---|
New advances in class III antiarrhythmic drug therapy.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrophysiology; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2000 |
Clinical differences between the newer antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dronedarone; Heart Conduction System; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sulfonamides | 2000 |
New antiarrhythmic drugs for the treatment of atrial fibrillation.
Topics: Aminobenzoates; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2002 |
[Drug therapy of ventricular arrhythmias - a contemporary perspective].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium Channel Blockers; Clinical Trials as Topic; Coronary Disease; Death, Sudden, Cardiac; Defibrillators, Implantable; Double-Blind Method; Follow-Up Studies; Heart Failure; Heart Ventricles; Humans; Hydantoins; Imidazoles; Imidazolidines; Meta-Analysis as Topic; Piperazines; Placebos; Primary Prevention; Prospective Studies; Quality of Life; Randomized Controlled Trials as Topic; Risk Factors; Time Factors | 2002 |
Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues.
Topics: Amiodarone; Anti-Arrhythmia Agents; Electrocardiography; Female; Heart Conduction System; Humans; Hydantoins; Imidazoles; Imidazolidines; Male; Phenethylamines; Piperazines; Risk Assessment; Risk Factors; Sex Factors; Sotalol; Sulfonamides; Tachycardia; Torsades de Pointes | 2003 |
Oral class III antiarrhythmics: what is new?
Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sotalol; Sulfonamides; Tachycardia, Supraventricular; Tachycardia, Ventricular; Treatment Outcome | 2004 |
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Indoles; Oxazines; Phenethylamines; Piperazines; Serotonin 5-HT4 Receptor Antagonists; Sulfonamides | 2004 |
A benefit-risk assessment of class III antiarrhythmic agents.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Combined Modality Therapy; Defibrillators, Implantable; Dronedarone; Heart Conduction System; Humans; Hydantoins; Imidazolidines; Ion Transport; Life Tables; Membrane Potentials; Meta-Analysis as Topic; Phenethylamines; Piperazines; Risk Assessment; Sotalol; Sulfonamides; Survival Analysis; Torsades de Pointes; Treatment Outcome | 2004 |
Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators.
Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Humans; Hydantoins; Imidazolidines; Piperazines; Secondary Prevention; Sotalol; Tachycardia, Ventricular; Treatment Outcome | 2007 |
Antiarrhythmic drugs: present and future.
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Drug Design; Humans; Hydantoins; Imidazolidines; Ion Channels; Piperazines; Sotalol | 2007 |
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits?
Topics: Amiodarone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anisoles; Anti-Arrhythmia Agents; Anticoagulants; Atrial Fibrillation; Bridged Bicyclo Compounds, Heterocyclic; Clinical Trials as Topic; Cyclopropanes; Dronedarone; Humans; Hydantoins; Imidazolidines; Piperazines; Pyrrolidines | 2008 |
[The research practice of anti-arrhythmic agents targeting on potassium ion channel].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Dronedarone; Humans; Hydantoins; Imidazolidines; Molecular Structure; Piperazines; Potassium Channel Blockers; Potassium Channels | 2011 |
Adjuvant antiarrhythmic therapy in patients with implantable cardioverter defibrillators.
Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Benzofurans; Defibrillators, Implantable; Humans; Hydantoins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazolidines; Mineralocorticoid Receptor Antagonists; Phenethylamines; Piperazines; Sotalol; Sulfonamides | 2014 |
11 other study(ies) available for azimilide and amiodarone
| Article | Year |
|---|---|
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Molecular hybridization, synthesis, and biological evaluation of novel chroman I(Kr) and I(Ks) dual blockers.
Topics: Animals; Anti-Arrhythmia Agents; Chromans; Drug Evaluation, Preclinical; Guinea Pigs; Heart Rate; Myocytes, Cardiac; Nucleic Acid Hybridization; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Rats; Rats, Sprague-Dawley; Sulfonamides | 2009 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
[Progress in the clinical use of anti-arrhythmic drugs (I)].
Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Child; Clinical Trials as Topic; Humans; Hydantoins; Imidazoles; Imidazolidines; Phenethylamines; Piperazines; Sulfonamides | 2003 |
Atrial-selective antiarrhythmic actions of novel Ikur vs. Ikr, Iks, and IKAch class Ic drugs and beta blockers in pigs.
Topics: Adrenergic beta-Antagonists; Amiodarone; Animals; Anti-Arrhythmia Agents; Atrial Function; Atropine; Biphenyl Compounds; Chromans; Flecainide; Heart Atria; Hydantoins; Imidazoles; Imidazolidines; Male; Phenethylamines; Piperazines; Potassium Channel Blockers; Potassium Channels; Propafenone; Propanolamines; Sotalol; Sulfonamides; Swine; Ventricular Function | 2004 |
Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bradycardia; Combined Modality Therapy; Defibrillators, Implantable; Drug Interactions; Humans; Hydantoins; Imidazolidines; Pacemaker, Artificial; Piperazines; Sotalol; Tachycardia, Ventricular; Treatment Outcome | 2004 |
The influence of extracellular acidosis on the effect of IKr blockers.
Topics: Acidosis; Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Humans; Hydantoins; Imidazolidines; Myocardial Infarction; Oocytes; Phenethylamines; Piperazines; Potassium Channels; Potassium Channels, Voltage-Gated; Quinidine; Sulfonamides; Trans-Activators; Xenopus laevis | 2005 |
A mechanism underlying compound-induced voltage shift in the current activation of hERG by antiarrhythmic agents.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Hydantoins; Imidazolidines; Membrane Potentials; Piperazines; Pyrimidinones; Xenopus laevis | 2011 |